Renovis Gains Funding From Pfizer To Further VR1 Receptor Research
This article was originally published in The Pink Sheet Daily
Executive Summary
Extension of existing collaboration with Pfizer will fund Renovis’ research in the area through June 30, 2008.
You may also be interested in...
Lilly Acquires Rights To TRPV-1 Receptor Antagonists From Glenmark
Eli Lilly is gaining a portfolio of molecules targeting the vanilloid-1 receptor, including Phase II candidate GRC 6211, through an agreement with Mumbai, India-based Glenmark Pharmaceuticals, announced Oct. 30
Lilly Acquires Rights To TRPV-1 Receptor Antagonists From Glenmark
Portfolio includes Phase II candidate GRC 6211 for treatment of pain conditions, including osteoarthritic pain.
Lilly Acquires Rights To TRPV-1 Receptor Antagonists From Glenmark
Portfolio includes Phase II candidate GRC 6211 for treatment of pain conditions, including osteoarthritic pain.